Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
Musim Alotaibi,1,2 Ahmed Ali,1,3 Duaa Bakhshwin,4 Yasser Alatawi,5 Sultan Alotaibi,6 Abdullah Alhifany,7 Badr Alharthi,2 Nasser Alharthi,2 Awatef Alyazidi,2 Yasmeen Alharthi,2 Aziza Alrafiah8 1Department of Pharmacology, King Abdulaziz University, Jeddah City, Kingdom of Saudi Arabia; 2Department of...
Main Authors: | Alotaibi M, Ali A, Bakhshwin D, Alatawi Y, Alotaibi S, Alhifany A, Alharthi B, Alharthi N, Alyazidi A, Alharthi Y, Alrafiah A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-09-01
|
Series: | International Journal of General Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/effectiveness-and-safety-of-favipiravir-compared-to-hydroxychloroquine-peer-reviewed-fulltext-article-IJGM |
Similar Items
-
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
by: Rahmet Guner, et al.
Published: (2021-03-01) -
Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
by: B. K. Romanov
Published: (2020-09-01) -
Effects of Hydroxychloroquine Plus Favipiravir Treatment on the Clinical Course and Biomarkers in Hospitalized COVID-19 Patients with Pneumonia
by: Leman Acun Delen, et al.
Published: (2022-01-01) -
Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study
by: Anıl Ucan, et al.
Published: (2021-05-01) -
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
by: Bandar Alosaimi, et al.
Published: (2022-11-01)